Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis
Tumor grading is a robust prognostic predictor in patients with neuroendocrine neoplasms (NEN) and guides therapy, especially in tumors with high proliferation. NEN can be separated into well-differentiated and poorly differentiated types. The more aggressive NEN have been further separated into neu...
Main Authors: | Sebastian C. B. Bremer, Gabi Bittner, Omar Elakad, Helen Dinter, Jochen Gaedcke, Alexander O. König, Ahmad Amanzada, Volker Ellenrieder, Alexander Freiherr von Hammerstein-Equord, Philipp Ströbel, Hanibal Bohnenberger |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/12/2828 |
Similar Items
-
Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma
by: Yuchan Li, et al.
Published: (2022-07-01) -
Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer
by: Shilpa Patil, et al.
Published: (2021-12-01) -
Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications
by: Giordano Antonio, et al.
Published: (2011-05-01) -
Enhancer of zeste homolog 2 regulates cell differentiation and proliferation in neuroblastoma
by: Amallia N. Setyawati, et al.
Published: (2014-12-01) -
Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors
by: Hajósi-Kalcakosz Szofia, et al.
Published: (2012-07-01)